Currently browsing

enero 12, 2021

Ventilator-associated pneumonia in critically ill patients with COVID-19

CONCLUSION: COVID-19 is associated with an increased risk of VAP, which is not fully explained by the prolonged duration of ventilation. The pulmonary dysbiosis caused by COVID-19, and the causative organisms of secondary pneumonia observed are similar to that seen in critically ill patients ventilated for other reasons.

Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase 3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)

The emergence of Gram-negative resistance during antibacterial therapy yields worse clinical outcomes and increased antimicrobial resistance worldwide. We evaluated the emergence of nonsusceptibility to ceftolozane/tazobactam and meropenem among participants with Pseudomonas aeruginosa lower respiratory tract isolates from ASPECT-NP, a phase 3, randomized, double-blind, multicenter study that demonstrated the noninferiority of a ceftolozane/tazobactam 3-g dose q8h versus a meropenem 1-g dose q8h…

Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterisation of Candida auris Detected in a Surveillance Program

A total of 15 Candida auris isolates from the SENTRY Antimicrobial Surveillance Program between 2006 and 2019 were combined with 21 isolates from other collections for the evaluation of antifungal susceptibility and synergy against anidulafungin plus voriconazole or isavuconazole using the checkerboard method. Surveillance isolates were analyzed for genetic relatedness and resistance mechanisms. Applying the tentative statistical epidemiological cutoff values and the Centers for Disease Control…